Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas

BACKGROUND: Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models. We investigated the maximum tolerated dose (MTD) of iniparib with monthly (m) and continuous (c) temozolomide (TMZ) dosing schedules in patients with m...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Neurooncol
Main Authors: Blakeley, Jaishri O., Grossman, Stuart A., Mikkelsen, Tom, Rosenfeld, Myrna R., Peereboom, David, Nabors, L. Burt, Chi, Andrew S., Emmons, Gary, Ribas, Ignacio Garcia, Supko, Jeffrey G., Desideri, Serena, Ye, Xiaobu
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869687/
https://ncbi.nlm.nih.gov/pubmed/26285766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1876-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki